LeMaitre Vascular (NASDAQ:LMAT) Lowered to Hold Rating by StockNews.com

StockNews.com cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research report sent to investors on Friday.

A number of other equities research analysts have also recently weighed in on LMAT. JMP Securities lifted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Barrington Research lifted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price on the stock. Finally, Oppenheimer restated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $100.69 on Friday. The company has a market capitalization of $2.26 billion, a P/E ratio of 55.02, a P/E/G ratio of 2.47 and a beta of 0.93. The company has a 50 day simple moving average of $97.47 and a 200-day simple moving average of $89.33. LeMaitre Vascular has a 1 year low of $52.88 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the previous year, the business earned $0.33 earnings per share. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. As a group, research analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.64%. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently modified their holdings of LMAT. Franklin Resources Inc. grew its stake in shares of LeMaitre Vascular by 5.2% during the third quarter. Franklin Resources Inc. now owns 12,646 shares of the medical instruments supplier’s stock worth $1,165,000 after purchasing an additional 627 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth about $181,000. Geode Capital Management LLC boosted its position in shares of LeMaitre Vascular by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock worth $50,403,000 after acquiring an additional 23,443 shares in the last quarter. M&T Bank Corp purchased a new position in shares of LeMaitre Vascular in the 3rd quarter valued at about $1,551,000. Finally, Barclays PLC raised its position in shares of LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after acquiring an additional 29,180 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.